MDxHealth SA ADR (MDXH) - Total Liabilities
Based on the latest financial reports, MDxHealth SA ADR (MDXH) has total liabilities worth $162.49 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MDxHealth SA ADR long-term investment intensity to see how much of total assets are deployed in long-term investments.
MDxHealth SA ADR - Total Liabilities Trend (2004–2025)
This chart illustrates how MDxHealth SA ADR's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of MDxHealth SA ADR.
MDxHealth SA ADR Competitors by Total Liabilities
The table below lists competitors of MDxHealth SA ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hiap Teck Venture Bhd
KLSE:5072
|
Malaysia | RM605.18 Million |
|
Kino Indonesia Tbk PT
JK:KINO
|
Indonesia | Rp2.83 Trillion |
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
India | Rs416.70 Million |
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
USA | $27.62 Million |
|
Cellectis
PA:ALCLS
|
France | €226.30 Million |
|
Reward Wool Industry Corp
TW:1423
|
Taiwan | NT$246.56 Million |
|
Jiin Ming Industry Co Ltd
TWO:3230
|
Taiwan | NT$345.61 Million |
|
Orion Energy Systems Inc
NASDAQ:OESX
|
USA | $34.56 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down MDxHealth SA ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MDxHealth SA ADR (MDXH) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MDxHealth SA ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MDxHealth SA ADR (2004–2025)
The table below shows the annual total liabilities of MDxHealth SA ADR from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $160.05 Million | +12.32% |
| 2024-12-31 | $142.49 Million | +16.87% |
| 2023-12-31 | $121.92 Million | +11.02% |
| 2022-12-31 | $109.82 Million | +289.81% |
| 2021-12-31 | $28.17 Million | +8.33% |
| 2020-12-31 | $26.01 Million | +24.41% |
| 2019-12-31 | $20.90 Million | +56.48% |
| 2018-12-31 | $13.36 Million | -10.79% |
| 2017-12-31 | $14.97 Million | -0.03% |
| 2016-12-31 | $14.98 Million | +11.13% |
| 2015-12-31 | $13.48 Million | +87.82% |
| 2014-12-31 | $7.18 Million | +48.07% |
| 2013-12-31 | $4.85 Million | +21.88% |
| 2012-12-31 | $3.98 Million | -9.01% |
| 2011-12-31 | $4.37 Million | -11.09% |
| 2010-12-31 | $4.92 Million | -42.36% |
| 2009-12-31 | $8.53 Million | -4.42% |
| 2008-12-31 | $8.92 Million | +5.83% |
| 2007-12-31 | $8.43 Million | +33.18% |
| 2006-12-31 | $6.33 Million | +30.25% |
| 2005-12-31 | $4.86 Million | +182.49% |
| 2004-12-31 | $1.72 Million | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more